Evidence map›Paper›PMID 37822314›Full record

ArticleHepatology forum2023

The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.

Serkan Yaras, Mehmet Demir, Sezgin Barutcu, Abdullah Emre Yildirim, Selim Gurel, Enver Ucbilek, Ilkce Akgun Kurtulmus, Meral Akdogan Kayhan, Sezgin Vatansever, Haydar Adanir and 23 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology forum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 1 institution in 1 country.

Serkan YarasDepartment of Gastroenterology, Mersin University, School of Medicine, Mersin, Turkiye.
Mehmet DemirDepartment of Gastroenterology, Mustafa Kemal University, School of Medicine, Hatay, Turkiye.
Sezgin BarutcuDepartment of Medical Sciences, Gaziantep University, School of Medicine, Gaziantep, Turkiye.
Abdullah Emre YildirimDepartment of Gastroenterology, Memorial Bahcelievler Hospital, Istanbul, Turkiye.
Selim GurelDepartment of Internal Medicine, Uludag University, School of Medicine, Bursa, Turkiye.
Enver UcbilekDepartment of Gastroenterology, Mersin University, School of Medicine, Mersin, Turkiye.
Ilkce Akgun KurtulmusDepartment of Internal Medicine, Ege University, School of Medicine, Izmir, Turkiye.
Meral Akdogan KayhanDivision of Gastroenterology, Department of Internal Medicine, Faculty of Health Sciences, Ankara City Hospital, Ankara, Turkiye.
Sezgin VatanseverDepartment of Gastroenterology, Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkiye.
Haydar AdanirDepartment of Internal Medicine, Akdeniz University, School of Medicine, Antalya, Turkiye.
Nilay DanisDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University, Baltimore, USA.
Serkan DumanDepartment of Gastroenterology, Toros State Hospital, Mersin, Turkiye.
Ilker TuranDepartment of Gastroenterology, Ege University, School of Medicine, Izmir, Turkiye.
Derya AriDivision of Gastroenterology, Department of Internal Medicine, Faculty of Health Sciences, Ankara City Hospital, Ankara, Turkiye.
Sukran KoseDepartment of Infectious Diseases and Clinical Microbiology, Dokuz Eylul University, School of Medicine, Izmir, Turkiye.
Huseyin AlkimDepartment of Gastroenterology, Sisli Etfal Training and Research Hospital, Istanbul, Turkiye.
Muhsin Murat HarputluogluDepartment of Internal Medicine, Inonu University, School of Medicine, Malatya, Turkiye.
Feyza DilberDepartment of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkiye.
Murat AkyildizDepartment of Gastroenterology, Koc University, School of Medicine, Istanbul, Turkiye.
Arif Mansur CosarDepartment of Gastroenterology, Karadeniz Technical University, School of Medicine, Trabzon, Turkiye.
Serdar DurakDepartment of Gastroenterology, Karadeniz Technical University, School of Medicine, Trabzon, Turkiye.
Goktug SirinDepartment of Gastroenterology, Kocaeli University, School of Medicine, Kocaeli, Turkiye.
Ayse KefeliDepartment of Gastroenterology, Tokat Gaziosmanpasa University, School of Medicine, Tokat, Turkiye.
Hale GokcanDepartment of Gastroenterology, Ankara University, School of Medicine, Ankara, Turkiye.
Ufuk AvciogluDepartment of Gastroenterology, Ondokuz Mayis University, School of Medicine, Samsun, Turkiye.
Talat AyyildizDepartment of Gastroenterology, Ondokuz Mayis University, School of Medicine, Samsun, Turkiye.
Orhan SezginDepartment of Gastroenterology, Mersin University, School of Medicine, Mersin, Turkiye.
Mesut AkarsuDepartment of Gastroenterology, Dokuz Eylul, School of Medicine, Izmir, Turkiye.
Dinc DincerDepartment of Gastroenterology, Akdeniz University, School of Medicine, Antalya, Turkiye.
Fatih GuzelbulutDepartments of Gastroenterology and Pathology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkiye.
Fulya GunsarDepartment of Gastroenterology, Ege University, School of Medicine, Izmir, Turkiye.
Ulus Salih AkarcaDepartment of Gastroenterology, Ege University, School of Medicine, Izmir, Turkiye.
Ramazan IdilmanDepartment of Gastroenterology, Ankara University, School of Medicine, Ankara, Turkiye.
Johns Hopkins Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed. Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.

Indexed as

Chronic hepatitis Cglecaprevir-pibrentasvirreal-life experience

Identifiers

PMID37822314
PMCPMC10564251
OpenAlexW4387563713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.